The Medicines Company to Present Data from its Investigational Anesthetic MDCO-700 at the ANESTHESIOLOGY® 2016 Annual Meeting and the ISAP 25th Annual Meeting

PARSIPPANY, N.J.–(BUSINESS WIRE)– The Medicines
Company (NASDAQ:MDCO) today announced that five abstracts with data
from its investigational anesthetic MDCO-700 (formerly, ABP-700)
development program will be presented at ANESTHESIOLOGY® 2016, the
annual meeting of the American Society of Anesthesiologists (ASA), being
held at the McCormick Place in Chicago from October 22-26, 2016 and at
the International Society for Anaesthetic Pharmacology 25th Annual
Meeting (ISAP) taking place at the Hyatt Regency Chicago on October 21,
2016.

Investigators will present data from the MDCO-700 Phase I clinical
program and preclinical animal studies evaluating infusion optimization,
safety, tolerability and pharmacokinetic and pharmacodynamic parameters
at both meetings in the form of oral and poster presentations.

About MDCO-700

MDCO-700 (formerly, ABP-700), an investigational product not approved
for commercial use in any market, is a novel, positive allosteric
modulator of the GABA-A receptor currently being developed for the
induction of general anesthesia and procedural sedation. MDCO-700 is
from a family of compounds invented by Dr. Douglas Raines at
the Massachusetts General Hospital.

About The Medicines Company

The Medicines Company is a biopharmaceutical company driven by an
overriding purpose—to save lives, alleviate suffering and contribute to
the economics of healthcare. The Company’s mission is to create
transformational solutions to address the most pressing healthcare needs
facing patients, physicians and providers in three critical therapeutic
areas: serious infectious disease care, cardiovascular care and surgery
and perioperative care. The Company is headquartered in Parsippany, New
Jersey, with global innovation centers in California and Switzerland.

Forward Looking Statements

Statements contained in this press release that are not purely
historical may be deemed to be forward-looking statements for purposes
of the safe harbor provisions under The Private Securities Litigation
Reform Act of 1995. Without limiting the foregoing, the words
« believes, » « anticipates, » « expects, » “views” and similar expressions
are intended to identify forward-looking statements. These
forward-looking statements involve known and unknown risks and
uncertainties that may cause the Company’s actual results, levels of
activity, performance or achievements to be materially different from
those expressed or implied by these forward-looking statements.
Important factors that may cause or contribute to such differences
include whether the clinical trials for our product candidates,
including MDCO-700, will advance in the clinical process on a timely
basis, or at all, or succeed in achieving their specified endpoints;
whether the Company is able to disclose clinical trial results on a
timely basis; whether physicians, patients and other key decision makers
will accept clinical trial results; whether the Company will make
regulatory submissions for its product candidates on a timely basis, or
at all; whether its regulatory submissions will receive approvals from
regulatory agencies on a timely basis, or at all; and such other factors
as are set forth in the risk factors detailed from time to time in the
Company’s periodic reports and registration statements filed with the
Securities and Exchange Commission including, without limitation, the
risk factors detailed in the Company’s quarterly report on Form 10-Q
filed with the Securities and Exchange Commission on August 5, 2016 ,
which are incorporated herein by reference. The Company specifically
disclaims any obligation to update these forward-looking statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161013005314/en/